Barclays on Centene (CNC): 'Medicaid Update Better Than Feared'

September 11, 2025 9:02 AM EDT Send to a Friend
Barclays analyst Andrew Mok reiterated an Equalweight rating and $33.00 price target on Centene (NYSE: CNC).The analyst comments "2025 EPS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login